LEFLUNOMIDE


Trade Names	ARAVA LEFLUNOMIDE
Synonyms	Arava HWA-486 L04AA13 Leflunomide Leflunomide medac Leflunomide ratiopharm Leflunomide teva Leflunomide winthrop NSC-677411 NSC-759864 Repso SU-101 SU101 SULOL
Status
Molecule Category	UNKNOWN
ATC	L04AA13
UNII	G162GK9U4W
EPA CompTox	DTXSID9023201


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VHOGYURTWQBHIL-UHFFFAOYSA-N
Smiles	Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
InChI	InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C12H9F3N2O2
Molecular Weight	270.21
AlogP	3.25
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	55.13
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	19.0

Pharmacology

Mechanism of Action	Action	Reference
Dihydroorotate dehydrogenase inhibitor	INHIBITOR	DailyMed


Protein: Dihydroorotate dehydrogenase Description: Dihydroorotate dehydrogenase (quinone), mitochondrial Organism : Homo sapiens Q02127 ENSG00000102967

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	-	-	-
Enzyme Oxidoreductase	-	10000-13000	-	-	12
Epigenetic regulator Writer Protein methyltransferase SET domain	-	-	-	-	4

Cross References

Resources	Reference
ChEBI	6402
ChEMBL	CHEMBL960
DrugBank	DB01097
DrugCentral	1552
FDA SRS	G162GK9U4W
Human Metabolome Database	HMDB0015229
Guide to Pharmacology	6825
KEGG	C07905
PharmGKB	PA450192
PubChem	3899
SureChEMBL	SCHEMBL5057
ZINC	ZINC000000004840

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).